Takeda is Dedicated to Finding Innovative Solutions in Metastatic Colorectal Cancer (mCRC)

Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related mortalities worldwide. With the global incidence of mCRC on the rise, treatment advancements in efficacy and tolerability are vital. Takeda Oncology is committed to bringing innovative solutions to evolve the treatment landscape in mCRC.